PMID- 30929188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2193-8245 (Print)
IS  - 2193-6528 (Electronic)
VI  - 8
IP  - 2
DP  - 2019 Jun
TI  - Efficacy and Safety of Wet Wipes Containing Hy-Ter((R)) Solution Compared with 
      Standard Care for Bilateral Posterior Blepharitis: A Preliminary Randomized 
      Controlled Study.
PG  - 313-321
LID - 10.1007/s40123-019-0182-x [doi]
AB  - INTRODUCTION: A novel treatment for posterior blepharitis which involves the use 
      of disposable wet wipes imbibed with a solution of terpinen-4-ol and hyaluronic 
      acid (Hy-Ter((R))) as well as aloe, natural anti-inflammatories and antiseptics 
      (Blephapad Combo; Novelty Technology Care, Milan, Italy) has been proposed. The 
      aim of this study was to compare the efficacy and safety of treatment with 
      Blephapad Combo with standard treatment. METHODS: We conducted 4-week, 
      open-label, randomized controlled study with a closed sequential design at the 
      Magna Graecia University of Catanzaro, Italy in which patients aged > 40 years 
      with symmetrical bilateral posterior blepharitis were enrolled. Each eye 
      represented a single experimental unit. Patients were randomly assigned using a 
      computer-generated randomization list to apply a reusable heated compress to the 
      eyelid of one eye before cleansing the eyelid with the Blephapad Combo wet wipe 
      (Blephapad Combo treatment arm) or to use the standard treatment of applying a 
      wet and warm gauze to the other eye (standard treatment arm), twice daily for 
      4 weeks. The primary endpoint was the percentage change from baseline to week 4 
      in meibomian gland dysfunction (MGD) grading scale scores. RESULTS: Eighteen 
      patients (9 men; 9 women) with a mean (+/- standard deviation) age of 
      66.9 +/- 9.03 years were included in the study. Compared with the eye receiving the 
      standard treatment, treatment with Blephapad Combo appeared to improve the MGD 
      total score after 4 weeks of treatment (mean change from baseline - 29.9 vs. 
      - 38.5%). The assessment of the investigators was that in 11 patients the eye 
      treated with Blephapad Combo showed greater benefit, in two patients the eye 
      treated with the standard treatment showed greater benefit and in four patients 
      there was no difference between treatments. Blephapad Combo was well tolerated, 
      with no serious adverse events (AEs) reported. Minor ocular AEs were reported in 
      44.4 and 38.9% of patients in the Blephard Combo and standard treatment arms, 
      respectively. CONCLUSIONS: Treatment with Blephapad Combo was more effective than 
      the standard treatment in ameliorating MGD in patients with posterior 
      blepharitis. Minor ocular AEs events were equally distributed between the two 
      treatments arms. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03301844.
FAU - De Luca, Valentina
AU  - De Luca V
AD  - Department of Ophthalmology, Magna Graecia University, Catanzaro, Italy.
FAU - Carnevali, Adriano
AU  - Carnevali A
AD  - Department of Ophthalmology, Magna Graecia University, Catanzaro, Italy.
FAU - Carnovale Scalzo, Giovanna
AU  - Carnovale Scalzo G
AD  - Department of Ophthalmology, Magna Graecia University, Catanzaro, Italy.
FAU - Piccoli, Gabriele
AU  - Piccoli G
AD  - Department of Ophthalmology, Magna Graecia University, Catanzaro, Italy.
FAU - Bruzzichessi, Donatella
AU  - Bruzzichessi D
AD  - Department of Ophthalmology, Magna Graecia University, Catanzaro, Italy.
FAU - Scorcia, Vincenzo
AU  - Scorcia V
AD  - Department of Ophthalmology, Magna Graecia University, Catanzaro, Italy. 
      vscorcia@libero.it.
AD  - Istituto internazionale di Ricerca e Formazione in Oftalmologia (IRFO), Forli, 
      Italy. vscorcia@libero.it.
LA  - eng
SI  - ClinicalTrials.gov/NCT03301844
PT  - Journal Article
DEP - 20190330
PL  - England
TA  - Ophthalmol Ther
JT  - Ophthalmology and therapy
JID - 101634502
PMC - PMC6513930
OTO - NOTNLM
OT  - Blephapad Combo
OT  - Blepharitis
OT  - Keratoconjunctivitis sicca
OT  - Meibomian gland
OT  - Randomized controlled trial
EDAT- 2019/04/01 06:00
MHDA- 2019/04/01 06:01
PMCR- 2019/03/30
CRDT- 2019/04/01 06:00
PHST- 2019/01/25 00:00 [received]
PHST- 2019/04/01 06:00 [pubmed]
PHST- 2019/04/01 06:01 [medline]
PHST- 2019/04/01 06:00 [entrez]
PHST- 2019/03/30 00:00 [pmc-release]
AID - 10.1007/s40123-019-0182-x [pii]
AID - 182 [pii]
AID - 10.1007/s40123-019-0182-x [doi]
PST - ppublish
SO  - Ophthalmol Ther. 2019 Jun;8(2):313-321. doi: 10.1007/s40123-019-0182-x. Epub 2019 
      Mar 30.